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Atherosclerosis is initiated and sustained by hyper-
cholesterolemia, which results in the generation of
oxidized LDL (OxLDL) and other metabolic byprod-
ucts that trigger inflammation. Specific immune
responses have been shown to modulate the inflam-
matory response during atherogenesis. The sialic
acid-binding immunoglobulin-like lectin G (Siglec-
G) is a negative regulator of the functions of several
immune cells, including myeloid cells and B-1 cells.
Here, we show that deficiency of Siglec-G in athero-
sclerosis-prone mice inhibits plaque formation
and diet-induced hepatic inflammation. We further
demonstrate that selective deficiency of Siglec-G in
B cells alone is sufficient to mediate these effects.
Levels of B-1 cell-derived natural IgMwith specificity
for OxLDL were significantly increased in the
plasma and peritoneal cavity of Siglec-G-deficient
mice. Consistent with the neutralizing functions of
OxLDL-specific IgM, Siglec-G-deficient mice were
protected from OxLDL-induced sterile inflammation.
Thus, Siglec-G promotes atherosclerosis and hepat-
ic inflammation by suppressing protective anti-in-
flammatory effector functions of B cells.INTRODUCTION
Atherosclerosis is a lipid-driven chronic disease of the artery wall
and the underlying cause of heart attacks and strokes, which ac-
counts for the majority of mortalities and morbidities in the world
(Libby et al., 2011). It is characterized by chronic inflammatory
responses to endogenous sterile triggers, such as oxidized
LDL (OxLDL), dying cells, and their metabolic byproducts that2348 Cell Reports 14, 2348–2361, March 15, 2016 ª2016 The Authortrigger tissue inflammation if not efficiently cleared (Tabas,
2010; Hotamisligil, 2006). Persistence of this inflammatory
response or its impaired resolution paves the way for chronic
inflammatory responses, which have been shown to propagate
associated pathologies such as vascular and hepatic inflamma-
tion (Tall and Yvan-Charvet, 2015). Thus, there is growing
interest in identifying mechanisms that enhance the immune
system’s capacity to prevent endogenously triggered inflamma-
tion and/or promote its resolution.
B cells, which can be subdivided into B-1 and B2 cells, are
emerging players in the chronic inflammation of metabolic dis-
eases, such as obesity, diabetes, and atherosclerosis (Tsiantou-
las et al., 2014; Winer et al., 2014; Zouggari et al., 2013; Perry
et al., 2012). B2 cells, which include follicular (FO) B cells and
marginal zone (MZ) B cells, have been shown to promote athero-
sclerotic lesion formation in murine models of atherosclerosis via
mechanisms that are largely unclear (Kyaw et al., 2010; Ait-Ou-
fella et al., 2010). On the other hand, selective transfer of B-1
cells, which can be further divided into B-1a and B-1b cells, pro-
tects mice from atherosclerosis (Kyaw et al., 2011; Rosenfeld
et al., 2015). One of the main functions of B-1 cells is the pro-
duction of natural IgM antibodies (NAb), which are pre-existing
germline encoded antibodies that arise without any conventional
T cell help and comprise approximately 80%of IgM antibodies in
unchallenged mice (Baumgarth et al., 2005). B-1a cells seem to
exhibit their atheroprotective effects via the secretion of NAb
(Tsiantoulas et al., 2014). Indeed, atherosclerosis-prone soluble
IgM-deficient mice develop accelerated atherosclerosis, though
the exact mechanism by which NAb protect is not entirely clear
(Lewis et al., 2009). We and others have suggested that NAb pro-
mote the neutralization and clearance of self-antigens, such as
dying cells and oxidized lipids (Tsiantoulas et al., 2012). These
studies indicate the importance of selective regulation of individ-
ual B cell subsets for appropriate responses to inflammatory trig-
gers. Moreover, the role of B-1 cells in atherosclerosis has only
been studied in immune-compromised animals, and their role
in animals that do not lack major compartments of the immunes
system remains elusive. In this regard, the sialic acid-binding
immunoglobulin-like lectin G (Siglec-G) is of particular interest
as it acts as negative regulator of the B-1a cell population size,
presumably via inhibiting B cell receptor dependent signaling
(Hoffmann et al., 2007; Ding et al., 2007). We and others have
previously shown that mice deficient in Siglec-G exhibit a nearly
10-fold expansion of B-1a cells along with a robust increase in
total serum IgM (Hoffmann et al., 2007; Ding et al., 2007). More-
over, we also found that Siglec-G deficiency results in an expan-
sion of IgMwith specificity for oxidation-specific epitopes (OSE),
which represent prototypic metabolic byproducts present on
OxLDL, dying cells, and circulating microparticles (Chou et al.,
2009; Tsiantoulas et al., 2015; Chang et al., 1999, 2004; Jellu-
sova et al., 2010). As excessive accumulation of OSE has been
suggested to be a key driver for inflammatory reactions in meta-
bolic diseases, such as atherosclerosis, non-alcoholic steatohe-
patitis, and diabetes (Miller et al., 2011; Walenbergh et al., 2013;
Horie et al., 1997), targeting Siglec-G may have beneficial thera-
peutic effects in chronic inflammation.
The expansion of B-1a cells has also been associated with
increased autoimmunity (Chan et al., 1997; Pao et al., 2007; Ish-
ida et al., 2006), which could accelerate atherosclerosis (Roman
and Salmon, 2007; Ma et al., 2008). Siglec-G deficiency has
been shown to result in an earlier onset of autoimmune disease
in the Murphy Roths Large/lymphoproliferative (MRL/lpr) lupus
mouse model and leads to mild autoimmunity in aging mice
with an over-activation of adaptive T and B cells (M€uller et al.,
2015; Bo¨kers et al., 2014). In addition, Siglec-G has also been
found to be expressed in and influence responses of myeloid
cells. For example, Siglec-G has been shown to be upregulated
by RNA viruses and to inhibit retinoic acid-inducible gene 1
(RIG-I) mediated IFN-b secretion by macrophages and dendritic
cells. In line with this, vesicular stomatitis virus (VSV)-infected
Siglec-G-deficient mice were found to display increased
IFN-b production and decreased viral load compared to
control mice (Chen et al., 2013). Moreover, dendritic cells of Si-
glec-G-deficient mice have been found to exhibit increased
pro-inflammatory cytokine secretion in response to multiple
danger-associated molecular patterns (DAMPs) (e.g., HSP70,
HSP90, and HMGB1). A detrimental role of Siglec-G deficiency
is further supported by the findings that Siglec-G-deficient mice
exhibit increased mortality in models of acetaminophen-
induced liver necrosis (Chen et al., 2009) and cecal ligation
and puncture-induced sepsis (Chen et al., 2011). Thus, all
studies so far indicate that Siglec-G functions as negative regu-
lator of inflammation, and Siglec-G deficiency may actually
propagate inflammatory responses. Because pro-inflammatory
cytokine production is a hallmark of metabolic inflammation,
the role of Siglec-G and the consequences of Siglec-G defi-
ciency in chronic inflammation and specifically in atheroscle-
rosis are entirely unknown.
Here, we investigated the role of Siglec-G in sterile chronic
inflammation in vivo. We demonstrate that total as well as B
cell-specific Siglec-G deficiency reduces atherosclerotic
lesion formation as well as hepatic inflammation in hypercho-
lesterolemic Ldlr/ mice. Moreover, we show that Siglec-G-
deficient mice are protected form OxLDL-induced inflamma-
tion in vivo.CellRESULTS
Siglec-G Deficiency in Cholesterol-Fed Ldlr/ Mice
Increases B-1a Cells and Natural IgM Antibodies
Siglec-G deficiency has been previously shown to result in an
expansion of OSE-specific NAb, which are hypothesized to
possess robust anti-inflammatory properties, particularly
against products of increased oxidative stress (Jellusova et al.,
2010). In agreement with previous data, non-atherosclerotic
Siglec-G/ mice have—compared to Siglec-G+/+ control
mice—significantly increased numbers of B-1a cells in the
spleen, increased numbers of CD138+ plasmablasts (B220+)
and plasma cells (B220lo) in the spleen and bone marrow, and
increased levels of OSE-specific IgM antibodies in the plasma
(Figures S1A–S1G). In order to investigate the effect of Siglec-
G deficiency in atherosclerosis, Ldlr/Siglec-G/ mice as
well as control Ldlr/ mice were fed an atherogenic diet for
8 weeks. Siglec-G deficiency did not affect body weight, or
plasma total cholesterol (TC), or triglycerides (TG) (Table 1).
Moreover, there was no significant difference in frequencies of
total or Ly6Chi and Ly6Clo monocytes in the peripheral blood of
these mice (Figures S2E and S2F). Frequencies of peripheral
blood B220+ B cells were also not different between the two
groups (Figure S2D).
Consistent with the previously described effect of Siglec-G
deficiency on B cells, numbers of splenic CD43+ B-1 cells
were increased in Ldlr/Siglec-G/ mice (Figures 1A and
1B). Numbers of CD3+ T cells, CD23+ FO B cells, and MZB cells
were not different between the groups (Table 1). Notably, the
numbers of the recently identified pro-atherogenic subset of
innate response activator (IRA) B cells in the spleen were signif-
icantly increased in Ldlr/Siglec-G/ mice compared to
Ldlr/ mice (Hilgendorf et al., 2014) (Figure S2A). Moreover,
compared to Ldlr/ mice, Ldlr/Siglec-G/ mice exhibited a
significantly increased frequency of B-1a cells in the peritoneal
cavity (Figures 1C and 1D), while the frequencies of B-1b or B2
cells were not significantly different between the groups (Figures
S2B and S2C).
We then assessed both total and OSE-specific IgM and IgG
antibody levels in plasma at baseline and after 8 weeks of
atherogenic diet. Levels of IgM antibodies were significantly
increased in Ldlr/Siglec-G/ mice at both time points (Fig-
ure 1E), while levels of total IgG antibodies were not different
(Figure 1F). Moreover, IgM titers to MDA-LDL as well as to
CuOx-LDL were also higher in Ldlr/Siglec-G/mice at base-
line and even further increased in response to atherogenic diet
feeding compared to controls (Figures 1G and 1H). Importantly,
expression of the antigen-specific IgM as a ratio of total IgM,
revealed a preferential expansion of IgM to MDA-LDL and
CuOx-LDL, while the relative levels of IgM to the atheroscle-
rosis-irrelevant antigen a-1,3-dextran were decreased (Fig-
ure 1I). On the other hand, IgG titers to these antigens were
elevated in Ldlr/Siglec-G/ mice only at baseline, but the
differences disappeared after 8 weeks of atherogenic diet (Fig-
ures S2G and S2H). Thus, even in the presence of extreme
hypercholesterolemia, Siglec-G deficiency results in an expan-
sion of B-1a cells and a concomitant increase of total and
OSE-specific IgM.Reports 14, 2348–2361, March 15, 2016 ª2016 The Authors 2349
Table 1. Parameters Overview of Experimental Groups:
Atherosclerosis Study
Ldlr/ Ldlr/Siglec-G/
(n = 16) (n = 14)
Metabolic Parametersa
Weights (g) 32.15 ± 0.53 31.2 ± 0.90
TC (mg/dL) 1,655.36 ± 70.24 1,633.65 ± 88.09
TG (mg/dL) 1,257.14 ± 55.37 1,284.38 ± 61.18
Atherosclerosis
en face (% of aorta) 4.22 ± 0.25 2.22 ± 0.20***
Innominate (3 104 mm2) 0.99 ± 0.17 0.43 ± 0.16*
Aortic origin
(3 104 mm2/section)
7.08 ± 0.88 8.69 ± 1.14
Necrotic area (% of total
lesion area)
14.8 ± 4.0 4.65 ± 1.21*
mac-3+ (% of cellular area) 65.83 ± 3.78 51.61 ± 2.53**
Hepatic Inflammation
Liver cholesterol (mg TC/mg
protein)
0.19 ± 0.01 0.19 ± 0.02
Liver TG (mg TG/mg protein) 0.68 ± 0.04 0.62 ± 0.06
Liver free fatty acids
(mg FFA/mg protein)
0.42 ± 0.02 0.37 ± 0.04
ALT (U/l) 72.9 ± 8.1 80.4 ± 6.6
Mac-1 (# positive cells/mm2) 150.04 ± 6.74 118.58 ± 6.14**
Ly6G (# positive cells/mm2) 68.38 ± 2.61 55.91 ± 2.32**
Serum Antibody Titers
Total IgM (mg/ml)
Baseline 0.26 ± 0.05 1.15 ± 0.05***
8 weeks HFD 0.87 ± 0.06 1.36 ± 0.06***
MDA-LDL IgM (RLU/100 ms)
Baseline 30,735 ± 1,534 54,680 ± 2,101***
8 weeks HFD 54,378 ± 2,196 80,773 ± 2,467***
CuOx-LDL IgM (RLU/100 ms)
Baseline 3,767 ± 585 12,459 ± 1,894***
8 weeks HFD 19,549 ± 2,443 40,649 ± 2,698***
Total IgG (mg/ml)
Baseline 0.24 ± 0.02 0.39 ± 0.07
8 weeks HFD 0.72 ± 0.06 0.89 ± 0.07
MDA-LDL IgG (RLU/100 ms)
Baseline 14,879 ± 1,855 22,392 ± 2,383*
8 weeks HFD 20,646 ± 1,800 23,699 ±1,870
CuOx-LDL IgG (RLU/100 ms)
Baseline 1,473 ± 91 3,220 ± 525**
8 weeks HFD 3,267 ± 356 4,463 ± 449
Spleen (Absolute Numbers 3 106)
T cells (CD3+) 34.18 ± 2.30 37.97 ± 3.04
B cells (B220+IgM+) 33.14 ± 2.44 38.64 ± 4.25
B-1 cells (B220+IgM+CD43+) 2.63 ± 0.32 5.56 ± 0.73***
MZ B cells
(B220+CD43CD23CD21hi)
0.71 ± 0.11 0.54 ± 0.09
Table 1. Continued
Ldlr/ Ldlr/Siglec-G/
(n = 16) (n = 14)
T2/FO B cells
(B220+CD43CD23+CD21+)
26.87 ± 2.26 34.0 ± 3.71
T1 B cells
(B220+CD43CD23CD21lo)
1.96 ± 0.18 2.71 ± 0.36
B220+CD43 CD23 CD21+ 1.50 ± 0.15 1.84 ± 0.15
IRA B cells
(CD19+IgMhighCD43+CD5+
CD138+CD93+MHCII+)
0.09 ± 0.01 0.18 ± 0.03**
Peritoneal Cavity (% Viable Cells)
B-1a cells
(B220+CD11b+CD5+)
out of B cells
27.74 ± 1.59 37.78 ± 2.60**
B-1b cells
(B220+CD11b+CD5)
out of B cells
15.57 ± 1.46 12.39 ± 1.41
B2 cells
(B220+CD11bCD5)
out of B cells
35.29 ± 1.84 33.2 ± 1.84
T cells (B220CD5+)
out of total
8.99 ± 1.10 9.42 ± 0.86
See also Figure S5.
aData are shown as mean ± SEM (* p % 0.05, ** p % 0.01, and *** p %
0.001).
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from Atherosclerosis
We then quantified the extent of atherosclerosis in the entire
aorta of both groups of mice by en face analyses, which revealed
a 50% reduced lesion size as a result of Siglec-G deficiency
(Figure 2A). Decreased atherosclerosis was also found in the
innominate arteries of Ldlr/Siglec-G/ mice compared
to Ldlr/ mice (Figure 2B). Moreover, while cross-sectional
analyses of the aortic origin did not reveal differences in lesion
size between the two groups (Figure 2C), lesions of Ldlr/
Siglec-G/ mice were clearly less complex with smaller
necrotic areas and reduced macrophage content (Figures 2D
and 2E). Lesional collagen content was not significantly different
between the two groups (Figure 2F), while deposition of IgM
was significantly increased in lesions of Ldlr/Siglec-G/
mice (Figure 2G). Thus, Siglec-G deficiency results in a profound
reduction of lesion size and complexity.
To identify whether the observed protective effects of
Siglec-G deficiency are mainly conferred by B cells, we gener-
ated bone marrow chimeric Ldlr/ mice with a selective
Siglec-G deficiency on B cells using a previously established
method (Sage et al., 2012; Fillatreau et al., 2002). Ldlr/ mice
were lethally irradiated and reconstituted with (1) bone marrow
from Siglec-G/ mice or Siglec-G+/+ littermate controls to
assess the role of Siglec-G deficiency in hematopoietic cells in
general, and (2) a mixture of 80% bone marrow from B cell-
deficient mMT mice and 20% from either Siglec-G/ mice or
Siglec-G+/+ littermate controls to assess Siglec-G deficiency
specifically in B cells. After a 4 week recovery period, mice
were fed an atherogenic diet for 10 weeks. Successfuls
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Figure 2. Siglec-G Deficiency Decreases
Atherosclerosis in Cholesterol-Fed Ldlr/
Siglec-G/ Mice
(A) Quantitative analysis of atherosclerosis in the
aorta. The data are expressed as percentage of
Sudan IV stained area of the entire aorta. The
representative pictures are shown on the right.
(B) Quantitative analysis of atherosclerotic lesions
in cross-sections of innominate arteries. The values
represent the average mm2 of four sections
throughout the innominate artery (300 mm). The
images show representative Masson’s trichrome
stains. The original magnification is 503, and the
scale bar represents 200 mm.
(C) Quantification of atherosclerotic lesion size in
cross-sections at the aortic origin. The values
represent the average mm2 of nine sections
throughout the entire aortic origin (400 mm). The
images show representative Masson’s trichrome
stains. The original magnification is 50X, and the
scale bar represents 200 mm.
(D) Quantification of necrotic areas in cross-sec-
tions at the aortic origin. The values represent the
percentages of necrotic areas of one section at
200 mm depth.
(E–G) Quantification of macrophage, collagen, and
IgM content in cross-sections at the aortic origin.
(E) Values represent the percentage of mac-3+ area
per cellular lesion area of one section per mouse at
200 mm depth.
(F) Values represent the percentage of Sirius Red+
area per total lesion area of one section per mouse
at 200 mm depth.
(G) Values represent the percentage of IgM+ area
per cellular lesion area of one section per mouse at
180 mm depth. Shown are the data of Ldlr/ and Ldlr/Siglec-G/ mice after 8 weeks of atherogenic diet. The symbols represent individual mice. The hor-
izontal bars represent the mean of each group and errors bars represent SEM (*p% 0.05, **p% 0.01, and ***p% 0.001).
See also Table 1.engraftment of the respective bone marrow was confirmed by
PCR of DNA isolated from bone marrow of recipients and of
sorted splenic B and non-B cells to demonstrate selective
Siglec-G deficiency (Figures S3A and S3B). In addition, the
lack of Siglec-G expression on splenic B cells was confirmed
by flow cytometry (Figure S3C).
Body weights, TC and TG levels in plasma, as well as fre-
quencies of peripheral blood monocytes and B cells were not
different between the experimental groups (Table 2; FiguresFigure 1. Siglec-G Deficiency in Cholesterol-Fed Ldlr/ Mice Increase
(A) Representative flow cytometry plots for splenic B220+CD43 B2 cells and B2
B cells.
(B) Absolute numbers of splenic B220+IgM+CD43+ B-1 cells.
(C) Representative flow cytometry plots for B cell subpopulations of the peritone
(D) Relative numbers of peritoneal B220+CD5+CD11b+ B-1a cells out of total B c
(E and F) Quantification of total IgM (E) and total IgG (F) antibodies in plasma.
triplicates.
(G and H) Titers of MDA-LDL IgM (G) and CuOx-LDL IgM (H) in plasma were deter
were diluted between 1:100 and 1:500 and antibody binding was measured in tr
(I) RLU of IgM antibodies to MDA-LDL and CuOx-LDL as well as a-1,3-dextran (
specific IgM per total IgM (a.u.). Shown are data of Ldlr/ and Ldlr/Siglec-G/
The horizontal bars represent the mean of each group and errors bars represent
See also Figures S1 and S2.
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were significantly increased in recipients of Siglec-G/ bone
marrow (whole and mixed bone marrow) compared to recipients
of control bone marrow (Figures 3A and S4D; Table 2). More-
over, total plasma IgM levels were significantly increased in
mice reconstituted with Siglec-G/ and mMT+Siglec-G/
bone marrow compared to their controls (Figure 3B), while
total plasma IgG levels were not different (Figure S4E).
IgM—but not IgG—levels to MDA-LDL and CuOx-LDL weres B-1a Cell-Derived IgM Antibodies
20+CD43+ B-1 cell subpopulations. The parental gate was set on B220+IgM+
al cavity. The parental gate was set on B220+ B cells.
ells.
The samples were diluted between 1:30,000 and 1:70,000 and measured in
mined by ELISA at baseline and after 8 weeks of atherogenic diet. The samples
iplicates. The data are expressed as relative light units (RLU) per 100 ms.
1:100) were normalized to total IgM concentrations and expressed as ratio of
mice after 8 weeks of atherogenic diet. The symbols represent individual mice.
SEM (*p% 0.05, **p% 0.01, and ***p% 0.001).
s
Table 2. Parameters Overview of Experimental Groups: Bone Marrow Transplantation Study
Ldlr/)
C57BL/6 Siglec-G/ mMT+C57BL/6 mMT+Siglec-G/
(n = 10) (n = 11) (n = 13) (n = 13)
Metabolic Parametersa
Weights (g) 25.54 ± 0.63 25.15 ± 0.67 25.72 ± 0.49 25.29 ± 0.73
TC (mg/dL) 758.33 ± 79.47 821.59 ± 66.53 884.67 ± 92.20 925.96 ± 78.29
TG (mg/dL) 595.83 ± 49.43 567.05 ± 48.57 661.46 ± 73.94 585.58 ± 46.60
Atherosclerosis
en face (% of aorta) 3.04 ± 0.38 0.59 ± 0.15*** 3.11 ± 0.24 1.17 ± 0.34***
Aortic origin (3 104 mm2/section) 4.84 ± 1.14 4.03 ± 1.13
Necrotic area (% of total lesion area) 5.20 ± 1.48 1.09 ± 0.66*
mac-3+ (% of total area) 54.96 ± 6.57 38.60 ± 4.95*
Hepatic Inflammation
Liver cholesterol (mg TC/mg protein) 0.22 ± 0.04 0.19 ± 0.03 0.23 ± 0.03 0.23 ± 0.03
Liver TG (mg TG/mg protein) 0.25 ± 0.04 0.21 ± 0.02 0.25 ± 0.03 0.22 ± 0.02
Liver free fatty acids (mg FFA/mg protein) 0.14 ± 0.01 0.12 ± 0.01 0.15 ± 0.01 0.15 ± 0.01
ALT (U/l) 109.1 ± 27.2 58.8 ± 11.5 47.6 ± 4.8 38.6 ± 3.0
Mac-1 (# positive cells/mm2) 120.69 ± 13.08 86.72 ± 8.95* 100.68 ± 6.33 79.41 ± 5.50*
Ly6G (# positive cells/mm2) 79.67 ± 5.82 58.58 ± 7.41* 74.40 ± 6.30 48.61 ± 4.04**
Serum Antibody Titers—10 Weeks HFD
Total IgM (mg/ml) 0.47 ± 0.10 0.92 ± 0.11** 0.55 ± 0.10 1.07 ± 0.10***
MDA-LDL IgM (RLU/100ms) 23,939 ± 2,848 32,989 ± 1,848** 23,514 ± 1,706 30,045 ± 943**
CuOx-LDL IgM (RLU/100ms) 4,877 ± 951 12,566 ± 1,583*** 5,714 ± 829 11,704 ± 1,045***
Total IgG (mg/ml) 0.47 ± 0.10 0.89 ± 0.10* 0.61 ± 0.09 0.98 ± 0.27
MDA-LDL IgG (RLU/100ms) 3,220 ± 633 6,126 ± 1,248 4,405 ± 701 4,012 ± 752
CuOx-LDL IgG (RLU/100ms) 2,885 ± 754 3,476 ± 769 1,827 ± 274 1,990 ± 452
Spleen (Absolute Numbers 3 106)
T cells (CD3+) 41.93 ± 4.76 37.51 ± 3.86 67.76 ± 17.05 42.90 ± 8.13
B cells (B220+IgM+) 66.80 ± 9.44 74.18 ± 9.22 43.85 ± 12.07 47.46 ± 13.18
B1 cells (B220+IgM+CD43+) 3.21 ± 0.38 6.15 ± 0.75** 2.82 ± 0.60 6.04 ± 1.32**
MZ B cells (B220+CD43CD23CD21hi) 1.98 ± 0.35 1.56 ± 0.26 4.58 ± 1.41 2.94 ± 1.28
T2/FO B cells (B220+CD43CD23+CD21+) 46.04 ± 5.43 54.25 ± 7.49 23.47 ± 7.63 25.28 ± 8.42
T1 B cells (B220+CD43CD23CD21lo) 3.42 ± 0.77 3.46 ± 0.35 3.68 ± 2.40 2.24 ± 0.72
B220+CD43 CD23 CD21+ 5.99 ± 1.18 5.48 ± 0.67 4.16 ± 1.05 5.38 ± 2.08
Peritoneal Cavity (% Viable Cells)
B-1a cells (B220+CD11b+CD5+) out of B cells 17.13 ± 1.40 31.85 ± 1.14*** 25.18 ± 0.62 46.20 ± 1.07***
B-1b cells (B220+CD11b+CD5) out of B cells 14.17 ± 1.24 12.47 ± 0.97 19.45 ± 1.29 15.96 ± 0.83*
B2 cells (B220+CD11bCD5) out of B cells 64.96 ± 2.32 48.47 ± 2.00*** 47.40 ± 1.94 29.88 ± 1.06***
T cells (B220CD5+) out of total 11.99 ± 1.19 15.07 ± 2.68 18.18 ± 5.04 13.97 ± 2.89
aData are shown as mean ± SEM (* p% 0.05, ** p% 0.01, and *** p% 0.001).also robustly and preferentially increased in recipient mice of
Siglec-G/ bone marrow (Figures 3C, 3D, and S4F–S4H).
Importantly, total and B cell-selective deficiency of Siglec-G
in the hematopoetic compartment resulted in a similar
reduction of atherosclerotic lesion formation (Figure 3E) and
a decreased lesional complexity with smaller necrotic areas
and fewer lesional macrophages in the aortic root (Fig-
ures 3F–3H). This indicates that Siglec-G deficiency on B cells
is primarily responsible for the protective effects in
atherogenesis.CellSiglec-G Deficiency in Mice Protects from Hepatic and
Systemic Inflammation
We have recently demonstrated that Ldlr/ mice develop he-
patic inflammation when fed an atherogenic diet (Bieghs et al.,
2012b). Therefore, we investigated the effect of Siglec-G defi-
ciency on hepatic inflammation in these mice. Atherogenic diet
feeding resulted in a robust steatosis of the liver of all experi-
mental mice. We found no significant differences in hepatic
cholesterol, hepatic TG, and hepatic free fatty acids between
the experimental groups. Consistent with only minimal liverReports 14, 2348–2361, March 15, 2016 ª2016 The Authors 2353
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Figure 3. Selective Siglec-G Deficiency in B
Cells Reduces the Development of Athero-
sclerosis
(A) Absolute numbers of splenic IgM+B220+CD43+
B-1 cells.
(B) Quantification of total IgM in plasma. The
samples were diluted 1:60,000 and measured in
triplicates.
(C and D) Binding of IgM antibodies to (C) MDA-
LDL and (D) CuOx-LDL was determined by ELISA.
The plasma samples were diluted between 1:100
and 1:500 and antibody binding was measured in
triplicates. The data are expressed as RLU/
100 ms.
(E) Quantitative analysis of atherosclerosis (en
face) in the entire aorta. The data are expressed as
percentage of Sudan IV stained area of the entire
aorta.
(F) Quantification of atherosclerotic lesion size in
cross-sections at the aortic origin. The values
represent the average mm2 of nine sections
throughout the entire aortic origin (400 mm).
(G) Quantification of necrotic areas in cross-sec-
tions at the aortic origin. The values represent
percentages of necrotic areas of one section at
200 mm.
(H) Quantification of the macrophage content in
cross-sections at the aortic origin. The values
represent percentages of mac-3+ area per total
lesion area of one section per mouse at 200 mm
depth. Shown are data of Ldlr/ mice recon-
stituted with Siglec-G+/+ [WT] versus Siglec-G/
[KO] and mMT+Siglec-G+/+ [WT] versus mMT+
Siglec-G/ [KO] bone marrow after 10 weeks of
atherogenic diet. The symbols represent individual
mice. The horizontal bars represent the mean of
each group and errors bars represent SEM (*p %
0.05, **p% 0.01, and ***p% 0.00).
See also Figures S3 and S4; Table 2.damage in this model, alanine aminotransferase (ALT) levels
were only moderately elevated, but also not different between
the two groups (Tables 1 and 2). In contrast, immunohistochem-
ical analyses of liver sections revealed a significantly reduced
infiltration of Ly6G+ neutrophils and mac-1+ macrophages in
the livers of Ldlr/Siglec-G/ mice compared to Ldlr/
mice (Figures 4A and 4B). A similar significant reduction in
neutrophil and macrophage infiltration was found in the livers
of Ldlr/ mice that were reconstituted with either Siglec-G/2354 Cell Reports 14, 2348–2361, March 15, 2016 ª2016 The Authorsor mMT+Siglec-G/ bone marrow (Fig-
ures S5A and S5B). To further define the
effects on hepatic inflammation between
Ldlr/ and Ldlr/Siglec-G/ mice, we
analyzed the expression of adhesion mol-
ecules, pro-inflammatory cytokines, and
chemokines in the liver of these mice. In
line with the reduced cell infiltration,
expression of intercellular adhesionmole-
cule (Icam) and vascular cell adhesion
protein (Vcam), tumor necrosis factor-
alpha (Tnf-a) and interleukin-18 (Il-18),C-C motif ligand 5 (Ccl5), C-X-C motif ligand 1 (Cxcl1), and
C-X-C motif ligand 2 (Cxcl2) were significantly reduced in the
livers of Ldlr/Siglec-G/mice compared to Ldlr/mice (Fig-
ure 4C). A similar though less pronounced decrease of inflamma-
tory gene expression was also observed in the livers of mice
lacking Siglec-G in B cells only (Figure S5C). Thus, Siglec-G defi-
ciency and Siglec-G deficiency on B cells reduces hepatic
inflammation, suggesting an important role in the development
of steatohepatitis.
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Figure 4. Siglec-G Deficiency Protects from Atherogenic Diet-Induced Hepatic and Systemic Inflammation
(A and B) Quantification of infiltrating neutrophils (A) andmacrophages (B) in liver sections of Ldlr/ versus Ldlr/Siglec-G/mice after 8 weeks of atherogenic
diet. The sections were stained with anti-Ly6G and anti-mac-1 antibody. The positively stained cells were counted and expressed as number of positive cells
per mm2. The representative pictures (original magnification 2003 and the scale bar represents 100 mm) are shown on the right.
(C) Relative gene expression of Icam, Vcam, Tnf-a, Il-18, Ccl5, Cxcl1, Cxcl2, and Saa1mRNA in livers of Ldlr/ versus Ldlr/Siglec-G/mice after 8 weeks of
atherogenic diet. The expression data of individual genes was normalized to the house-keeping gene S12 and expressed relative to the expression in Ldlr/
control mice.
(D) Quantification of SAA levels in plasma of Ldlr/ versus Ldlr/Siglec-G/mice at baseline and after 8 weeks of atherogenic diet. The samples were diluted
1:300 and measured in triplicates.
(E) Quantification of TNFa, IL-6, IL-18, CCL2, CXCL1, and CXCL2 in plasma of Ldlr/ versus Ldlr/Siglec-G/ mice after 8 weeks of atherogenic diet by
multiplex assay. The samples were diluted 1:2. The data represent mean ± SEM of 9–13 mice per group (*p% 0.05, **p% 0.01, and ***p% 0.001).
See also Figure S5.To assess systemic markers of inflammation in these mice,
we quantified hepatic mRNA expression and the circulating
levels of serum amyloid A (SAA), which in mice represents
an acute phase protein that is induced during chronic inflam-
mation (Uhlar and Whitehead, 1999). Expression of Saa1 was
significantly reduced in the livers of Ldlr/Siglec-G/ mice
compared to Ldlr/ mice (Figure 4C). Moreover, while plasmaCellSAA levels increased after 8 weeks of atherogenic diet in
Ldlr/, this was not the case for Ldlr/Siglec-G/ mice
(Figure 4D). SAA levels in Ldlr/ mice that were reconstituted
with mMT+Siglec-G/ or mMT+wild-type (WT) bone marrow
after 10 weeks of atherogenic diet were lower in both groups,
consistent with a more moderate degree of inflammation, but
still showed a tendency toward reduced levels as a result ofReports 14, 2348–2361, March 15, 2016 ª2016 The Authors 2355
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Figure 5. OxLDL-Induced Sterile Peritonitis
Is Suppressed by Siglec-G Deficiency
(A and B) Quantification of absolute numbers of
Ly6G+ neutrophils (A) and Ly6Chi inflammatory
monocytes (B) in the PLF of C57BL/6 mice at
baseline, as well as 2, 6, and 12 hr after OxLDL in-
jections.
(C) Quantification of total IgM in the PLF of
Siglec-G+/+ and Siglec-G/ mice. The samples
were diluted 1:20 and measured in triplicates.
(D) Binding of IgM to CuOx-LDL in the PLF of
Siglec-G+/+ and Siglec-G/ mice was determined
by ELISA. The samples were undiluted and antibody
binding was measured in triplicates. The data are
expressed as relative RLU/100 ms.
(E and F) Quantification of absolute numbers of
Ly6G+ neutrophils (E) and Ly6Chi monocytes (F) in
the PLF of Siglec-G+/+ and Siglec-G/ mice at
baseline, 2, and 6 hr after i.p. injection of OxLDL.
(G and H) Quantification of CXCL1 (G) and CXCL2
(H) in the PLF of Siglec-G+/+ and Siglec-G/ mice
at indicated time points by ELISA. The samples
were undiluted and measured in duplicates. The
data represent mean ± SEM of 3–7 mice per
group and are a representative example of three
individual experiments (*p% 0.05, **p% 0.01, and
***p% 0.001). See also Figures S6 and S7.Siglec-G deficiency (Figure S5D). To better characterize
the inflammatory responses in these mice, we quantified
the plasma levels of cytokines (TNF-a, IL-6, and IL-18)
and chemokines (CCL2, CXCL1, and CXCL2) that have
been previously identified to contribute to different patho-
genic responses in atherosclerosis and hepatic inflam-
mation (Ait-Oufella et al., 2011; Weber and Noels, 2011).
Of all cytokines and chemokines tested, plasma levels of
CXCL1 were significantly reduced both in Ldlr/Siglec-G/
mice (Figure 4E) and Ldlr/ mice lacking Siglec-G in
B cells only compared to their respective controls (Fig-
ure S5E). Notably, Cxcl1 has been shown to be promi-
nently induced in macrophages and endothelial cells stimu-
lated with OxLDL and mediates the recruitment of
neutrophils and monocytes (Stewart et al., 2010; Berliner
et al., 1990).
Thus, atherogenic diet is associated with increased inflamma-
tion in Ldlr/mice, and this effect is suppressed in mice lacking
Siglec-G. Collectively, these data point to a strong anti-inflam-
matory effect of Siglec-G deficiency in diet-induced hepatic
and systemic inflammation.2356 Cell Reports 14, 2348–2361, March 15, 2016 ª2016 The AuthorsSiglec-G Deficiency Protects from
OxLDL-Induced Sterile Peritonitis
Because we have previously shown that
OSE-specific NAb inhibit pro-inflamma-
tory effects of epitopes of OxLDL (Tsian-
toulas et al., 2015; Imai et al., 2008), which
is considered a major driver of vascular
and hepatic inflammation (Miller et al.,
2011; Walenbergh et al., 2013), we evalu-
ated the effect of Siglec-G deficiency inan OxLDL-induced sterile inflammation model in vivo. For this,
we first established a sterile peritonitis model that allowed us
to monitor the recruitment of neutrophils and monocytes in the
peritoneal lavage fluid (PLF) of WT C57BL/6 mice 2, 6, and
12 hr after they had received an intraperitoneal (i.p.) injection
of OxLDL. Compared to baseline, mice injected with OxLDL
exhibited a marked recruitment of Ly-6G+ neutrophils into the
peritoneal cavity already after 2 hr, which remained significantly
different, but gradually declined after 6 and 12 hr (Figures 5A, S6,
and S7A). Similarly, peritoneal recruitment of Ly6C+CD11bint
inflammatory monocytes was also induced following i.p. injec-
tion of OxLDL, but only peaked 6 hr after the injection, consistent
with the delayed recruitment of monocytes during inflammatory
processes (Figures 5B and S7A).
To investigate the anti-inflammatory effect of natural IgM
associated with Siglec-G deficiency, we compared the dy-
namics of inflammatory cell recruitment during OxLDL-induced
peritonitis in Siglec-G+/+ and Siglec-G/ mice, respectively.
Consistent with the dramatic increase of IgM antibodies in the
plasma of Siglec-G/ mice, we observed >3-fold higher levels
of total and >9-fold higher levels of OxLDL-specific IgM in
the PLF of Siglec-G/ mice at baseline (Figures 5C and 5D). At
baseline, the numbers of peritoneal macrophages, which repre-
sent the cellular population that is primarily involved in respond-
ing to OxLDL, were not significantly different between Siglec-G+/
+ andSiglec-G/mice (Figure S7C).Siglec-G/miceshoweda
significantly reduced recruitment of neutrophils 2 hr after i.p. in-
jection of OxLDL compared to Siglec-G+/+ mice, while after
6 hr, no differences between the two groups were observed (Fig-
ure 5E). Consistent with this, OxLDL-induced secretion of CXCL1
and CXCL2 was nearly absent in the peritoneal cavity of
Siglec-G/miceat this timepoint (Figures 5Gand5H). At 6 hours
after i.p. injection of OxLDL, the recruitment of Ly-6C+CD11bint
inflammatory monocytes appeared lower in Siglec-G/ mice
(Figure 5F). In contrast, Siglec-G deficiency had no effect on
neutrophil recruitment in response to injection of thioglycollate
(another sterile trigger), indicating that Siglec-G-deficient mice
do not have defective inflammatory responses in general and
demonstrating specificity for inflammatory responses triggered
by OSE (Figure S7D). In summary, Siglec-G deficiency results in
a significant inhibition of the inflammatory response to OxLDL
in vivo. The markedly reduced infiltration of neutrophils in
Siglec-G/mice in response to i.p. injection of OxLDL indicates
direct neutralization of its pro-inflammatory moieties and more
efficient clearance mediated by OSE-specific IgM.
DISCUSSION
In this study, we demonstrate a pathogenic role for Siglec-G in
atherosclerosis and hepatic inflammation. We could show that
Siglec-G deficiency in atherosclerosis-prone Ldlr/ mice leads
to a marked reduction of atherosclerotic lesion burden as well
as decreased hepatic inflammation. This effect is specific for
Siglec-G deficiency in B cells that results in higher B-1 cell
numbers and a robust and preferential increase in OSE-specific
IgM antibodies, which neutralize OxLDL-induced inflammation
in vivo.
Siglec-G is primarily expressed on B cells, with slightly higher
expression levels on B-1a cells than on conventional B2 cells
(Hoffmann et al., 2007), but it has also been shown to be ex-
pressed on dendritic cells and eosinophils (Hutzler et al., 2014;
Pfrengle et al., 2013). A suppressive role of Siglec-G in non-B
cells has been suggested in drug-induced liver damage, as
Siglec-G deficiency results in increased production of pro-in-
flammatory cytokines, including IL-6, TNF-a, and MCP-1,
following stimulation with DAMPs that are released in this setting
(Chen et al., 2009). Nevertheless, our data clearly identify an anti-
inflammatory effect of Siglec-G deficiency in cholesterol-fed
Ldlr/ mice as documented by reduced hepatic expression of
adhesion molecules, pro-inflammatory cytokines, and chemo-
kines as well as lower CXCL1 levels in plasma. Moreover, our
data demonstrate Siglec-G deficiency to be protective in a
model of OxLDL-induced peritonitis, while it has been shown
to aggravate inflammation in cecal ligation and puncture-
induced polybacterial peritonitis. These detrimental effects of
Siglec-G deficiency have been shown to be dependent on its
interaction with the glycosylphosphatidylinositol (GPI)-anchored
co-stimulatory protein CD24 (Chen et al., 2011). CD24 has been
shown to recognize DAMPs and to allow Siglec-G to suppressCellpro-inflammatory signaling via pattern-recognition receptors,
which can be disrupted by bacterial sialidases, but not by LPS.
In our study, Siglec-G deficiency conferred a protective effect
against another type of sterile trigger, OxLDL, as Siglec-G-defi-
cient mice exhibited decreased inflammation in an OxLDL-
induced peritonitis model. Presumably, the sterile inflammation
induced by OxLDL also does not disrupt the interaction of
CD24 and Siglec-G, suggesting that Siglec-G deficiency pro-
tects via other mechanisms than CD24.
It has also been shown that RNA viruses evade anti-viral de-
fenses by upregulating Siglec-G in macrophages and dendritic
cells, resulting in diminished production of type I interferons
that are essential in the host defense against viruses (Chen
et al., 2013). As a consequence of this, Siglec-G deficiency re-
sults in increased production of type I interferons, which notably
have been shown to promote atherosclerosis in several studies
(Ait-Oufella et al., 2011). Because we have shown that Siglec-G
deficiency protects from atherosclerosis, this pathway seems to
be not relevant in this setting. In line with this, stimulation
of peritoneal and bone-marrow derived macrophages with
OxLDL does not induce Siglec-G expression (data not shown).
Taken together, our data argue against a role of Siglec-G in
myeloid cells with respect to atherosclerosis and hepatic inflam-
mation. Moreover, we provide clear evidence that the protective
effect of Siglec-G deficiency is mediated by B cells, indicating
that the function of Siglec-G on B cells is dominant. In B cells,
Siglec-G is expressed in all stages throughout B cell develop-
ment (Pfrengle et al., 2013; Hutzler et al., 2014). Therefore, its
functional role in autoimmunity has been studied, particularly in
aging mice (M€uller et al., 2015). Old Siglec-G/ mice have
been shown to exhibit an increased expression of activation
markers on T cells and conventional B2 cells, suggesting a
more general over-activation of the adaptive immune system in
these settings. However, the effects described in our study are
more consistent with the increased production of protective
B-1 cell-derived NAb by Siglec-G-deficient mice. In line with
previous data, we demonstrate that Siglec-G deficiency also
resulted in a dramatic expansion of peritoneal B-1a as well as
splenic B-1 cells in atherosclerotic mice. FO B cells and MZB
cells remained unchanged in Ldlr/Siglec-G/ mice as well
as in the bone marrow chimeric mice. Thus, our data support a
protective role of B-1 cells in atherosclerosis (Tsiantoulas
et al., 2014). Notably, we did observe a robust increase of the
recently described IRA B cells in the spleens of atherosclerotic
Ldlr/Siglec-G/ mice. These cells have been suggested to
originate from B-1a cells and have been shown to promote
atherosclerotic lesion formation (Hilgendorf et al., 2014). Thus,
although our data are in line with a B-1 cell origin of IRA B cells,
the protective effects of B-1 cells dominate in atherosclerotic
mice lacking Siglec-G. Previous studies demonstrated an
atheroprotective effect of adoptive transfer of B-1a cells into
splenectomized Apoe/ mice and of B-1b cells into Rag-1/
Apoe/ mice (Kyaw et al., 2011; Rosenfeld et al., 2015). These
studies address the role of B-1 cells only in immune-compro-
mised mice on top of existing differences in various immune
cell populations, such as lack of splenocytes or total lympho-
cytes as a result of splenectomy or Rag-1 deficiency, respec-
tively. However, they do not provide a conclusive answer onReports 14, 2348–2361, March 15, 2016 ª2016 The Authors 2357
the role of B-1 cells in atherosclerosis in an intact host. Our data
provide clear and direct genetic evidence that expansion of B-1a
cells in intact mice mediates atheroprotection.
One of the major functions of B-1 cells is the secretion of nat-
ural IgM antibodies, which have been suggested to mediate the
atheroprotective effect of B-1 cells. Kyaw et al. (2011) showed
that accelerated lesion formation in splenectomized Ldlr/
mice, which exhibit diminished peritoneal B-1a cell numbers
and reduced serum IgM, is reversed by the adoptive transfer of
B-1a cells. This effect was dependent on the capacity of B-1a
cells to secrete IgM, as adoptive transfer of B-1 cells from
secreted IgM/ donors did not have any effect. The atheropro-
tective role of NAbs is further supported by the fact that Ldlr/
mice deficient in secreted IgM develop increased atheroscle-
rosis compared to Ldlr/ controlmice (Lewis et al., 2009). These
data also suggested that increasing IgM titers above and beyond
normal plasma levels could confer atheroprotection. Interest-
ingly, hypercholesterolemia raises plasma IgM levels, presum-
ably as part of an endogenous defense mechanism against
increased accumulation of metabolic waste products (Khoo
et al., 2015). However, this protective response is not sufficient
to prevent the formation of atherosclerotic plaques and hepatic
inflammation. Deficiency of Siglec-G results in an even greater
increase of IgM antibodies despite excessive hypercholesterole-
mia, and thus Siglec-G may be an attractive target for therapeu-
tic intervention, for example, by blocking antibodies.
Natural IgM exhibit house-keeping functions by promoting the
clearance of dying cells and cellular debris (Avrameas, 1991;
Notkins, 2004). These properties of natural IgM are in part medi-
ated by their ability to recognize OSE, which are also present in
OxLDL (Miller et al., 2011).We have previously shown that immu-
nization of high-fat diet-fed Ldlr/ mice with heat-killed pneu-
mococci led to the expansion of a natural IgM clone recognizing
OxLDL (T15/E06) and significantly decreased atherosclerotic
lesion formation and hepatic inflammation (Binder et al., 2003;
Bieghs et al., 2012b). These data suggested that anti-OxLDL
IgM protect from atherosclerosis and liver inflammation. Indeed,
epidemiological studies in humans indicate that high levels of
OxLDL-specific IgM are associated with a lower incidence of
cardiovascular disease (Tsiantoulas et al., 2014). Of note, Si-
glec-G deficiency, which results in atheroprotection, leads to a
preferential increase of IgM with specificity for different epitopes
of OxLDL in plasma.
Several mechanisms exist by which OxLDL-specific IgM
exhibit atheroprotective properties, including their ability to
inhibit foam cell formation by blocking scavenger receptor-medi-
ated uptake of OxLDL bymacrophages (Tsiantoulas et al., 2014).
In addition, anti-OxLDL IgM prevent the accumulation of
apoptotic cells by promoting their uptake by macrophages
(Ogden et al., 2005; Chou et al., 2009). In line with this, we
show smaller necrotic areas in lesion of Ldlr/Siglec-G/
mice. Moreover, anti-OxLDL IgM inhibit inflammation by compo-
nents of OxLDL in vitro (Imai et al., 2008). In agreement with a
neutralizing effect of anti-OxLDL IgM, we now show reduced
CXCL1 and CXCL2 secretion as well as neutrophil infiltration
into the peritoneum in vivo following injection of OxLDL into
Siglec-G/ mice, which have >9-fold higher levels of anti-
OxLDL IgM in the peritoneal cavity compared to WT controls.2358 Cell Reports 14, 2348–2361, March 15, 2016 ª2016 The AuthorMoreover, plasma levels of CXCL1 were significantly reduced
in Siglec-G-deficient atherosclerotic mice. OxLDL has been
shown to induce Cxcl1 expression in macrophages via a co-
operation of CD36/TLR4/TLR6, and CXCL1 represents a key
mediator of leukocyte recruitment in atherosclerosis (Stewart
et al., 2010). Moreover, both macrophage CD36 and TLR-4
expression have been shown to promote atherogenesis and he-
patic inflammation. Thus, increased natural IgM with specificity
for OxLDL have the capacity to inhibit atherosclerotic lesion for-
mation and hepatic inflammation in Siglec-G-deficient mice by
neutralizing the pro-inflammatory properties of OxLDL.
In conclusion, we provide evidence that expansion of natural
IgM antibodies beyond physiological plasma levels protect
from atherosclerosis and hepatic inflammation. Exploiting these
mechanisms, for example, by blocking the inhibitory effect of Si-
glec-G, may represent a therapeutic approach to enhance and
strengthen the endogenous defense mechanisms to protect
from cardiovascular disease and associated metabolic disor-
ders, such as non-alcoholic steatohepatitis.
EXPERIMENTAL PROCEDURES
An expanded version of experimental procedures can be found in Supple-
mental Information.
Animals and Intervention Studies
All experimental protocols were approved by the institutional animal experi-
mentation committee and the Austrian Ministry of Science. All mice were on
a C57BL/6 background. Ldlr/ and mMT mice were purchased originally
from The Jackson Laboratories (Bar Harbor, Maine, USA). The generation of
C57BL/6 Siglec-G/ mice has been described elsewhere (M€uller et al.,
2015). Siglec-G/ mice were further crossed with Ldlr/ mice to obtain
Ldlr/Siglec-G/ and Ldlr/Siglec-G+/+ mice. For intervention studies,
three cohorts of 12-week-old male Ldlr/Siglec-G/ mice (n = 14) and
Ldlr/Siglec-G+/+ (n = 16) littermate controls were fed an atherogenic diet
containing 21% milk fat and 0.2% cholesterol (TD88137, Ssniff Spezialdia¨ten)
for 8 weeks. Bone marrow transplantation studies were performed as previ-
ously described (Binder et al., 2004; Sage et al., 2012; Fillatreau et al., 2002)
and as described in Supplemental Information.
Analysis of Atherosclerotic Lesions
The extent of atherosclerosis was assessed in a blinded fashion in en face
preparations of the entire aorta and in cross-sections through the aortic origin
by computer-assisted image analysis as previously described (Binder et al.,
2003, 2004; Cardilo-Reis et al., 2012).
Liver Histology
The left lobes of livers were harvested and four equal pieces were snap frozen
in liquid nitrogen for further analyses. Frozen liver sections (7 mm) were stained
for the presence of infiltrating macrophages and neutrophils as described pre-
viously (Bieghs et al., 2012a). For the presence of neutrophils, sections were
stained with mouse anti-Ly6G (1:50; BD PharMingen). Cell nuclei were coun-
terstained with hematoxylin (Klinipath). Pictures were taken with a Nikon digital
camera DMX1200 and ACT-1 v2.63 software (Nikon). The number of positive-
stained cells was counted in six pictures (200 3) per liver per mouse to deter-
mine the level of liver inflammation.
Flow Cytometry
Peritoneal exudate cells (PEC), splenocytes, bone marrow cells, and blood
leukocytes were harvested as previously described (Cardilo-Reis et al.,
2012) and stained as indicated in Supplemental Information. Stained cell
populations were analyzed by multiparameter flow cytometry using a BD
FACSCalibur (BD Bioscience) or BD FACS Fortessa, respectively. Dead cells
and doublets were excluded by forward- and side-scatter and data weres
analyzed using the FlowJo v10 data analysis software (Tree Star). Criteria used
to identify the various cell populations are provided in Table 1.
Plasma Antibody and Protein Analyses
Total IgM levels were measured by a chemiluminescent-based sandwich
ELISA as described previously (Chou et al., 2009). Total IgG levels were
measured in plasma using a commercially available ELISA (Mouse IgG total
ELISA Ready-SET-Go!, eBioscience). Cu2+-OxLDL (CuOx-LDL) and MDA-
LDL were prepared as described previously (Chou et al., 2009). a-1,3-dextran
was a gift of John F. Kearney (University of Alabama at Birmingham, Alabama,
USA). Antigen-specific antibody titers were measured by chemiluminescent
ELISA as previously described (Binder et al., 2003). OxLDL-specific IgMper to-
tal IgM ratios were calculated based on the measurements of specific IgM at
non-saturating dilutions (expressed as RLU/100 ms) and total IgM quantities
of each individual sample. Data are expressed as a.u. of these ratios. SAA
levels were measured in plasma diluted 1:300 using a commercially available
ELISA for mouse SAA (Tridelta Development).
Measurement of Chemokines/Cytokines in Plasma and PLF
A panel of chemokines and cytokines (IL-6, TNF-a, CCXL1, CXCL2, CCL2, and
IL-18) was measured in mouse plasma (1:2 dilution) with ProcartaPlex Multi-
plex Immunoassays (eBioscience) according to the manufacturer’s protocol.
Analysis was performed with the xMAP Technology by Luminex. Levels of
CXCL1 and CXCL2 in the PLF were determined by using mouse CXCL1/KC
DuoSet ELISA and Mouse CXCL2/MIP-2 DuoSet ELISA, respectively accord-
ing to the manufacturer’s protocol (R&D Systems).
Murine Sterile Peritonitis
Siglec-G/mice andWT littermate controls (8–12weeks of age) were injected
i.p. with sterile CuOx-LDL (tested for endotoxin levels by chromogenic
Limulus amoebocyte assay; <0.05 ng LPS/mg protein) suspended in 600 ml
of sterile PBS-BSA (25 mg/grambodyweight) or a comparable volume of sterile
thioglycollate (LipidMAPS) (25 ml/g body weight). At selected time points, mice
were sacrificed, and PEC were collected by lavaging the peritoneum with 6 ml
of sterile PBS+1%BSA. PEC were pelleted for 10min at 300 g, and processed
for flow cytometry, as described above. Cell-free lavage fluid was stored in
aliquots and further processed for ELISA measurements.
Statistical Analysis
Data were analyzed using GraphPad Prism version 6.0 for Windows
(GraphPad Software). Normal distribution of data was assessed, and statisti-
cal analyses were performed by unpaired Student’s t-test to determine statis-
tical significance between the groups. Data points, which were more than 23
SD of themean, were excluded as statistical outliers. Exclusion of these values
did not change the significance of the results. Data are presented as the
mean ± SEM and considered significant at p % 0.05 (*p % 0.05, **p % 0.01,
and ***p% 0.001, respectively).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at http://dx.doi.
org/10.1016/j.celrep.2016.02.027.
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